Sentence examples for vigor study from inspiring English sources
The virtual immersive gaming to optimize recovery (VIGOR) study is a randomized controlled trial of the effects of virtual reality games to encourage lumbar spine flexion among individuals with chronic low back pain and fear of movement.
A second rise in November 2000 occurred during the same month as the publication of the Vioxx Gastrointestinal Outcomes Research (VIGOR) study.[31], [32] The exceedence vanished within one month of the withdrawal of rofecoxib.
In the VIGOR study rofecoxib 50 mg had a relative risk of 2 compared with naproxen for the composite end-point of death, stroke, and AMI [ 30].
Concern continues regarding the cardiovascular safety of highly selective CSIs, because of the unexpected but significantly higher rate of cardiovascular thrombotic events with rofecoxib than with naproxen seen only in the VIGOR study [ 10].
Rofecoxib was recently withdrawn from the market due to an increased risk of cardiovascular events found in both the Vioxx Gastrointestinal Outcomes Research (VIGOR) study and the recent Adenomatous Polyp Prevention on Vioxx (APPROVe) trial.
However, as noted, the FDA has added a description of the cardiovascular findings in the VIGOR study to the label for rofecoxib along with a statement urging "caution in patients with a medical history of ischaemic heart disease... .......... [ 15].
The lower 18% lethality value observed by Lexicon might be related to examining few genes coding for transcription factors and structural proteins and hybrid vigor from studying C57BL6/J 129SvEv hybrid mice.
It is possible that our meta-analysis was confounded by pharmaceutical company support of several naproxen studies in the wake of the increased risk of AMI seen with rofecoxib in the VIGOR (VIOXX GI Outcomes Research) study [ 29, 30].
It is possible that this plausible self-regulating effect of the AtWRI1 expression could be another key to the high levels of TAG accumulated without apparent negative effects on plant vigor in that study.
Patients with a previous history of ulcers comprised 4.1% of the SUCCESS population, about half the proportions in 2 other major coxib clinical trials, the Celecoxib Long-Term Arthritis Safety Study (CLASS) [ 21] and the Vioxx Gastrointestinal Outcomes Research study (VIGOR) [ 22].
Previous work in this system has documented larval hybrid vigor both in field studies of admixed contemporary populations [ 38] and experimental mesocosms [ 27], but has also demonstrated high embryonic mortality [ 34].
